BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cash for Anti-Cancer Device Helps Creo Medical Expand


1/18/2013 9:02:04 AM

A medical devices company has undergone significant expansion after raising £3m to develop a device to help prevent bowel cancer. Chepstow-based Creo Medical raised the £3m in an equity co-investment to further develop its CRoMa system, which promises safe, precise and cost-effective treatment of pre-cancerous lesions in the bowel. The equity investment came from an angel investor syndicate and the company’s first institutional investor, Finance Wales. Finance Wales’ £1.36m investment was pivotal to Creo’s decision to locate its new headquarters at Chepstow’s Beaufort Park. Since the move, Creo has completed CRoMa’s product development and trials. It has also geared up production and is on course for full commercialisation in 2013. “These are exciting times for us,” said Creo Medical’s chief executive, Craig Gulliford. “This latest investment round has helped us accelerate the development of our latest product, which has great potential to improve success rates in the prevention of bowel cancer.” Expansion has also seen Creo recruit five new staff members, including John Bradshaw as its new chief financial officer. Mr Bradshaw was previously CFO of Cardiff-based Gyrus Medical. He said: “Having worked with several of the Creo team before, I instantly saw the strength and experience of the team who are developing an exciting technology to address an expanding market. I was delighted to join the team as they embark on an exciting period for the business.” Mr Gulliford was keen to point out the importance of the most recent investment to Creo. “Securing £3m of new capital was a significant development for us, as was Finance Wales’ backing as our first institutional investor,” he said. “We’ve made excellent progress this year since opening our Chepstow headquarters and have achieved all our key milestones. Our new CRoMa system is already attracting great interest from surgeons keen to use it as soon as it becomes available.”

Read at News Release

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES